A Virtual Reality View of Molecularly Targeted and Chemotherapeutic Agents with Sequencing Therapy in the Management of Advanced Gastric and Gastroesophageal Junction Cancers

View Activity

PROGRAM CHAIR

Charles S. Fuchs, MD, MPH
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Hospital
New Haven, CT

FACULTY

Peter Enzinger, MD
Director, Center for Esophageal and Gastric Cancer
Institute Physician
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

David H. Ilson, MD, PhD
Attending Physician
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This enduring activity will cover the treatment and management of patients with advanced gastric cancer and gastroesophageal junction cancer.

TARGET AUDIENCE

This activity is designed to educate community oncologists, nurses, pharmacists, and other healthcare providers involved in the care of patients with advanced gastric cancer and gastroesophageal junction cancer.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Assess both monotherapy and combination regimens that have demonstrated efficacy in advanced and metastatic gastric and gastroesophageal junction cancers across all lines of therapy
  • Review medical society guidelines for the treatment of advanced gastric cancer and gastroesophageal junction cancer from first line through subsequent lines of treatment
  • Describe the development of treatment strategies and the management of adverse events to optimize efficacy and quality of life in the care of patients with advanced GC and GEJ

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 2.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment and management of patients with advanced gastric cancer or gastroesophageal junction cancer.

CNE Credits:
2.0 ANCC Contact Hour(s)

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Fuchs has served as a consultant for Eli Lilly, Entrinsic Health, Fire Prime Therapeutics, Merrimack Pharmaceuticals, Bayer, Agios Pharmaceuticals, Genentech, Merck, Gilead, Dicerna Pharmaceuticals, Sanofi, and Taiho Pharmaceutical.
Dr. Ilson is a consultant for AstraZeneca, BMS, Lilly, Merck, Pfizer, Pieris and Roche.
Dr. Enzinger is a consultant for Astellas, Five Prime, Merck and Taiho.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content was peer reviewed by a nurse reviewer. The reviewer has nothing to disclose

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Melissa A Johnson, Senior Program Manager for Med Learning Group, has nothing to disclose.
Flavia Piazza, PhD, VP Scientific and Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures;
2. Participate in the activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate via email within 30 days.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

RELEASE DATE: March 23, 2018

EXPIRATION DATE: March 23, 2019

View Activity

Participation Statement
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.

Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.